tbuckley/cabot-search huggingface dataset:
On Retirement
Authors: Henry M. Seidel
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PWE-139 Liver stiffness measurement for assessment of patients receiving methotrexate: Abstract PWE-139 Table 1
Authors: R Greig, E Forrest
Journal: Gut (2015)

<h3>Introduction</h3> Liver biopsy is recommended for the assessment of Methotrexate (MTX) related liver disease. Transient Elastography (TE) to measure Liver Stiffness (LSM) has been used to assess the degree of hepatic fibrosis. We investigated the use of TE to assess MTX treated patients. <h3>Method</h3> Between October 2008 and July 2014 patients with suspected MTX-related liver damage referred to Glasgow Royal Infirmary underwent TE using the Fibroscan®. A quality scan was defined as a scan with a &gt;60% success rate and an IQR &lt;30% (Quality 30). Readily available parameters were derived from computer records including standard liver blood tests, pro-collagen-3 N-terminal peptide (P3NP) when measured, the AST to Platelet Ratio Index (APRI), the Fib-4 score and abdominal ultrasound features of liver disease. <h3>Results</h3> 147 scans were performed on 118 patients. Most patients had chronic psoriasis (70; 59%) or arthritis (43, 36%). The median age was 55 (range 19–87) and median follow up was 838 days (range 79–2080). Seven scans were unsuccessful: in 5 obesity was cited as a factor. Quality 30 scans were obtained 99 (71%) of cases. Rank Correlations (p values; 95% CI for significant correlations): In the Psoriatic group there was a correlation with P3NP (p = 0.029; 0.0295, 0.463). LSM &gt;7.9 was found in 52 scans (37%); 33 were Quality 30. Advice to discontinue MTX was given in 35 of these cases, with further assessment and/or monitoring advised in the remainder. Serial scans have been performed in 21 patients continuing MTX. The median interval between the serial scans was 510 days (331–1205). The median change in LSM between scans was 0.3 (-8.4 – 8.1) but the LSM rose in 15 cases: with a median rise of 1.6 (range 0.1 – 8.1). In 89 cases an abdominal ultrasound result was available: 55 cases (62%) had fatty change present. During follow-up there were 10 deaths: there were no recorded liver-related deaths. <h3>Conclusion</h3> LSM is feasible in patients treated with MTX related. It correlates with other markers of fibrosis such as APRI and P3NP in some patient groups. LSM should be considered as part of the assessment of MTX hepatoxicity in order to advise on treatment changes and selection for liver biopsy. <h3>Disclosure of interest</h3> None Declared.
Thrombopoietin Promotes the Survival of Murine Hematopoietic Long-Term Reconstituting Cells: Comparison With the Effects of FLT3/FLK-2 Ligand and Interleukin-6
Authors: Takuya Matsunaga, Takashi Kato, Hiroshi Miyazaki, Makio Ogawa
Journal: Blood (1998)
AB0760 Symphysis Pubis Joint Change in Ankylosing Spondylitis
Authors: B.S. Koo, Y. Song, S. Lee, K.B. Joo, T.-H. Kim
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In radiographic evaluation of ankylosing spondylitis (AS) patients, it was well known that the principle sites of involvement are the sacroiliac joints with spine and symphysis pubis joint involvement is very rare [1,2]. But several recent studies suggest that symphysis pubis joint changes of AS patients are frequently seen on pelvic MRI [3,4]. <h3>Objectives</h3> The purpose of this study is to evaluate the proportion of symphysis pubis joint involvement in ankylosing spondylitis (AS) patients and to find out the correlation between symphysis pubis joint change and the modified Stoke spinal score (mSASSS). <h3>Methods</h3> A retrospective evaluation was performed in 222 AS male patients who had pelvis radiograph with cervical and lumbar spine radiographs in Hanyang University Hospital for Rheumatic Diseases from Aug 2004 to Feb 2014. The radiographs were examined by two experienced radiologist and evaluated according to the radiographic damage score: 0 - no damage, 1 - subtle irregularity and subchondral sclerosis, 2 - erosion, 3 - ankylosis or 4 - total ankylosis. We evaluated clinical characteristics of AS patients and analyzed radiologic changes. The relationship between symphysis pubis joint damage score and mSASSS in two different time points was investigated using generalized estimating equations (GEE). <h3>Results</h3> The mean age of AS patients was 30.6±8.3 years and the mean disease duration was 7.1±4.6 years. Among them, 105 patients (47.3%) showed radiologic damage in symphysis pubis joint. In comparison between normal group (score 0) and abnormal group (score 1-4) of symphysis pubis joint, abnormal group showed longer symptom duration (10.1±7.0 vs 7.6±5.8 years, p=0.004) and higher mSASSS (18.6±17.0 vs 14.3±13.4, p=0.038) than normal group. A significant Pearson correlation was found between the radiographic damage score of symphysis pubis joint and mSASSS (r=0.205, p=0.020). Using GEE analysis, an increase of one symphysis pubis joint damage score led to an increase of 16.7 mSASSS units (p=0.029). <h3>Conclusions</h3> The proportion of symphysis pubis involvement in AS male patients was 47.3%. Moreover, the radiographic change of symphysis pubis was correlated with radiographic damage of spinal joint. <h3>References</h3> Calin A, Elswood J. The relationship between pelvic, spinal and hip involvement in ankylosing spondylitis–one disease process or several? Br. J. Rheumatol. 27, 393–395 (1988). Vinson EN, Major NM. MR imaging of ankylosing spondylitis. Semin. Musculoskelet. Radiol. 7, 103–113 (2003). Jans L, Van Langenhove C, Van Praet L, et al. Diagnostic value of pelvic enthesitis on MRI of the sacroiliac joints in spondyloarthritis. Eur. Radiol. 24, 866–871 (2014). Yilmaz MH, Ozbayrak M, Kasapcopur O, Kurugoglu S, Kanberoglu K. Pelvic MRI findings of juvenile-onset ankylosing spondylitis. Clin. Rheumatol. 29, 1007–1013 (2010). <h3>Disclosure of Interest</h3> None declared
In the Middle: 1954-63-Historical Note&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: M B Shimkin
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article In the Middle: 1954-63-Historical Note Get access Michael B. Shimkin, M.D. Michael B. Shimkin, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 62, Issue 5, May 1979, Pages 1295–1317, https://doi.org/10.1093/jnci/62.5.1295 Published: 01 May 1979 Article history Received: 19 May 1978 Accepted: 31 October 1978 Published: 01 May 1979
FRI0556 Are Serum Biomarker Levels Associated with Sciatica?
Authors: S. Hider, K. Konstantinou, D.L. Mattey, E.M. Hay
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Pro-inflammatory cytokines released from the intervertebral disc are considered key in the pathogenesis of sciatica. There is increasing interest in whether biologics such as anti-TNF therapies could be used for treatment of sciatica. Data has shown increased cytokine expression in lumbar disc and CSF samples. Fewer studies have examined whether serum cytokine levels are associated with sciatica. <h3>Objectives</h3> To compare the levels of cytokines and other inflammatory markers in patients with sciatica with those with low back pain (LBP) alone. <h3>Methods</h3> GP consulters aged &gt;18 with LBP and sciatica were recruited. Participants underwent a standardised clinical assessment, lumbar spine MRI and had serum samples taken. Participants were classified as having MRI confirmed disc prolapse with nerve root compression or not and by their leg pain intensity (VAS &gt;7, yes/no). Key cytokines, chemokines and matrix metalloproteinases (MMPs) implicated in sciatica pathogenesis including TNFα, IL-1,IL-6, MMP1,3,8, aggregan and monocyte chemoattractant protein-1 (MCP-1/CCL-2) were assayed in duplicate using commercial multiplex detection kits and measured with a Luminex suspension array system. Median levels were compared between the groups. <h3>Results</h3> Of the 17 biomarkers tested, patients with MRI defined radiculopathy (n=53) had higher levels of MCP-1 than those without (n=63) (median MCP-1 level 301.4 vs 255.7 pg/ml, p=0.04). Patients with severe leg pain and MRI changes (n=30) also had higher levels of MCP-1 than those without (n=85) (median MCP-1 315.9 vs 256.7 pg/ml, p=0.009). None of the other cytokines including TNF, IL-6 or other pro-inflammatory markers showed significant differences between the groups (either by leg pain intensity or MRI radiculopathy). <h3>Conclusions</h3> In this cohort, levels of the chemokine MCP-1 appeared to be higher in patients with positive MRI findings than in patients with low back pain alone. No significant differences in serum TNF or IL-6 levels was seen between patients with sciatica and those with LBP alone. Further studies are required to confirm this finding and investigate further the role of MCP-1 in sciatica pathogenesis. <h3>Acknowledgements</h3> We acknowledge the participating patients and GP practices together with the support of the ATLAS study team and the research staff at the Haywood Hospital <h3>Disclosure of Interest</h3> None declared
&lt;TITLE&gt;Gastroesophageal Reflux in Children&lt;/TITLE&gt;
Authors: Y Vandenplas
Journal: JAMA (2000)

Gastroesophageal reflux is so common in infancy that the phenomenon is usually considered to be physiologic. However, reflux in infants has also been related to severe morbidity and even death. The art of selecting the optimal approach to treating reflux in children is to avoid over-investigations and over-treatment as well as the other extreme of neglecting the problem. Therefore investigations should be limited to a minimum and the treatment chosen should be effective but at the same time as free of side effects as possible. Since the basic pathophysiologic mechanism of reflux disease in children is a motility problem, prokinetic agents are indicated for the treatment of this condition. The very low incidence of side effects with these agents is also a relevant advantage to their use in the treatment of pediatric reflux disease.
PWE-112 ‘ring liver’ – a novel clinical tool to enhance frontline management of the patient with decompensated cirrhosis
Authors: N Shah, J Heffernan, B Malek, PA Berry, SJ Thomson
Journal: Gut (2015)

Chk1 (checkpoint kinase 1) is a serine-threonine kinase that is critical for G2/M arrest in response to DNA damage. Chk1 phosphorylates Cdc25C at serine-216, a major regulatory site, in response to DNA damage. Furthermore, Chk1 also phosphorylates Cdc25A on serine 123 which accelerates its degradation through the ubiquitin-proteasome pathway and arrests cells in late G2-phase after DNA damage. In the present study, we demonstrated that Chk1 phosphorylates pro-apoptotic protein BAD (<b>B</b>cl-2/Bcl-X<sub>L</sub>-<b>A</b>ntagonist, causing cell <b>D</b>eath) in vitro. In vitro phosphorylation analysis with various mouse BAD peptides has revealed two phosphorylation sites for Chk1 at serine-155 and serine-170. When wild-type and mutant BAD (S155A) constructs were transfected into 293T cells, an association between BAD and Chk1 was observed by co-immunoprecipitation. In addition, there was an increase in the phosphorylation of serine-155 following DNA damage by adriamycin treatment. Our results suggest that Chk1 associates with BAD and phosphorylates the BAD protein at serine-155. Taken together, our results suggest that Chk1 may inactivate BAD by associating with and phosphorylating residues critical for BAD function in response to DNA damage.
Drug use by the polysurgical patient
Authors: R A Devaul, R C Hall, L A Faillace
Journal: American Journal of Psychiatry (1978)

The authors compared the drug use of 23 patients with 5 or more major surgeries (mean number of surgeries = 9.8) with that of a matched control group (mean number of surgeries = 1). Total drug use of the polysurgical patients was 3.7 times greater than that of the controls and involved narcotics, analgesics, barbiturates, and minor tranquilizers. The authors describe the characteristics of polysurgical patients, one of which is chronic pain, and propose a treatment plan that involves psychological intervention for the patient and his or her family.
Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms
Authors: A Wolkin, M Sanfilipo, E Duncan, B Angrist, A P Wolf, T B Cooper, J D Brodie, E Laska, J P Rotrosen
Journal: American Journal of Psychiatry (1996)

The purpose of this report was to determine 1) the effects of chronic haloperidol treatment on cerebral metabolism in schizophrenic patients, 2) the relation between negative symptoms and haloperidol-induced regional changes in cerebral glucose utilization, and 3) the relation between metabolic change and clinical antipsychotic effect.Cerebral glucose utilization, as determined by position emission tomography (PET), was studied in 18 male schizophrenic subjects before and after chronic treatment with haloperidol at a standardized plasma level.Overall, haloperidol caused a widespread decrease in absolute cerebral glucose metabolism. The cerebral metabolic response to haloperidol was blunted in patients with high pretreatment negative symptom scores.Taken together with the results from a previously reported PET study of the effects of an acute amphetamine challenge (in which 14 of the current subjects participated), these data suggest that the negative symptom complex is associated with diminished cerebral response to change in dopaminergic activity. This deficit cannot be solely accounted for by structural differences.
A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
Authors: Patrick Y. Wen, David A. Reardon, Surasak Phuphanich, Robert Aiken, Joseph C. Landolfi, William T. Curry, Jay-Jiguang Zhu, Michael J. Glantz, David M. Peereboom, James Markert, Renato V. LaRocca, Donald O'Rourke, Karen L. Fink, Lyndon J. Kim, Michael L. Gruber, Glenn Jay Lesser, Edward Pan, Santosh Kesari, Elma S. Hawkins, John Yu
Journal: Journal of Clinical Oncology (2014)

2005 Background: The trial investigated whether adding tumor-antigen-loaded DC vaccine to surgery and chemoradiation would improve overall survival (OS) or progression free survival (PFS). Methods: HLA-A1+ and/or -A2+ resected patients with residual tumor <1 cm3 received 6 weeks of concurrent temozolomide (TMZ) and radiation. 124 patients were randomized 2:1 to receive ICT-107 (autologous PBMC-derived DC pulsed with 6 synthetic peptide CTL epitopes targeting the GBM tumor and tumor stem cell-associated antigens MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL-13Rα2) or its matching control (unpulsed DC). Patients then received induction ICT-107 or control QWx4 followed by maintenance TMZ, 5 days/mo for 12 mos. Booster vaccinations occurred at 1, 3, and 6 mos after induction, and every 6 mos thereafter. The trial concluded and data were evaluated at 67 events. Results: ICT-107 was generally safe and well tolerated, with no imbalance in AEs between the treated and control groups. PFS improved by 2 mos in the ICT-107 ITT group (p=0.02 two-sided, hazard ratio (HR)=0.56). In the per-protocol (PP) group (117 patients receiving all 4 induction vaccinations), p=0.01 two-sided, HR=0.53, and the difference in median PFS increased to 3 mos. The median OS favored ICT-107 by 2 mos in the ITT and 3 mos in the PP groups. However, the number of events was small and OS did not reach statistical significance (p=0.58 two-sided, HR=0.87, and p=0.40 two-sided, HR=0.79, respectively). Median follow-up from randomization was 13.6 mos. In the ICT-107 group, vaccine activation markers IL12 and HLA-DR were predictive of OS (p-values < 0.05). There were no correlations in the placebo group. Conclusions: This is the first randomized, placebo-controlled immunotherapy trial in GBM to positively affect a clinical outcome, PFS. Although OS improvement was not statistically significant at the 67/124 event point, patients continue to be followed for OS, allowing periodic updating of the primary endpoint and assessment of long-term survival. Analysis of QOL, and correlation of both tumor antigen expression and vaccine immunologic response with OS are in process.
SAT0415 Performance of Anti-Nuclear Antibodies (ANA) for Classifying Systemic Lupus Erythematosus (SLE): A Systematic Literature Review and Meta-Regression of Diagnostic Data
Authors: N. Leuchten, R. Brinks, A. Hoyer, M. Schoels, M. Aringer, S. Johnson, G. Schmajuk, D. Daikh, T. Dörner, G. Bertsias
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> EULAR and ACR have jointly funded a project to improve existing SLE classification criteria, aiming at earlier and more accurate classification of the disease. This abstract reports on an early phase of that project. ANA constitute the immunological hallmark of SLE, and ANA testing is widely used for SLE diagnosis based on its reportedly high sensitivity. Although indirect immunofluorescence on Hep-2 cells (IIF-Hep2) is considered the gold standard of ANA testing (1), the performance of different ANA titers and the possibility to include ANA as entry criterion for the classification of SLE have not been systematically evaluated. <h3>Objectives</h3> To review the published literature on the performance of IIF-Hep2 ANA testing for the classification/diagnosis of SLE. <h3>Methods</h3> A systematic literature search was conducted in MEDLINE and EMBASE for articles published between January 1990 and March 2014. The research question was structured according to PICO (Population, Intervention, Comparator, Outcome) format rules, and PRISMA recommendations were followed where appropriate. Meta-regression analysis for diagnostic tests was performed using the ANA titer as independent variable and sensitivity and specificity as dependent variables. <h3>Results</h3> A total of 3,919 publications were screened in abstract and title and 623 articles were evaluated in full-text. Of these, 60 matched the eligibility criteria and were included in the analysis. The included studies comprised 10,089 SLE patients in total, of whom 9,587 (95.0%) were reported to be ANA positive at various titers. For ANA at titers of 1:40, 1:80 and 1:160, meta-regression gave sensitivity values of 98.8% (95% confidence interval [CI] 98.0-99.3%), 98.1% (CI 97.1-98.8%) and 95.4% (CI 93.0–97.0%), respectively. The corresponding specificities were 75.1% (CI 64.3-83.5%), 83.3% (CI 74.9-89.3%) and 93.2% (CI 88.6-96.0%), respectively. <h3>Conclusions</h3> The results of this systematic literature search and meta-regression confirm the high sensitivity of a positive ANA test for SLE. While no decision has so far been made, these data suggest that ANA at a titer of 1:80 could be a reasonable entry criterion for SLE classification criteria. <h3>References</h3> Agmon-Levin et al, Ann Rheum Dis 2014; 73: 17ff <h3>Disclosure of Interest</h3> None declared
Associations Between Tumor Types in a Large-Scale Carcinogenesis Study of CF-1 Mice2
Authors: N. E. Breslow, N.E. Day, L. Tomatis, V. S. Turusov
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Associations Between Tumor Types in a Large-Scale Carcinogenesis Study of CF-1 Mice Get access N. E. Breslow, N. E. Breslow Search for other works by this author on: Oxford Academic PubMed Google Scholar N.E. Day, N.E. Day Search for other works by this author on: Oxford Academic PubMed Google Scholar L. Tomatis, L. Tomatis Search for other works by this author on: Oxford Academic PubMed Google Scholar V. S. Turusov V. S. Turusov Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 1, January 1974, Pages 233–239, https://doi.org/10.1093/jnci/52.1.233 Published: 01 January 1974 Article history Received: 27 July 1973 Accepted: 12 September 1973 Published: 01 January 1974
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with <i>ALK-</i>positive non-small cell lung cancer (NSCLC).
Authors: D. R. Camidge, Y. Bang, E. L. Kwak, A. T. Shaw, A. J. Iafrate, R. G. Maki, B. J. Solomon, S. I. Ou, R. Salgia, K. D. Wilner, D. B. Costa, G. Shapiro, P. LoRusso, P. Stephenson, Y. Tang, K. Ruffner, J. W. Clark
Journal: Journal of Clinical Oncology (2011)

2501 Background: The anaplastic lymphoma kinase (ALK) fusion gene is a key oncogenic driver in a subset of patients with NSCLC. Crizotinib is a potent and selective, ATP-competitive, small molecule ALK inhibitor. Patients with ALK-positive NSCLC may benefit from targeted ALK inhibitors. Methods: An ongoing open-label, multicenter, 2-part, phase I trial is investigating the safety, tolerability, pharmacokinetics, and antitumor activity of crizotinib in patients with advanced cancer. Updated safety and response data and preliminary PFS data from an expanded ALK-positive cohort of patients with NSCLC in part 2 of the study are reported. Patients received oral crizotinib 250 mg BID in 28-day cycles. Results: Currently, 119 patients with ALK-positive NSCLC have enrolled and 116 are evaluable for response, with 94 in follow-up for survival. Median age was 51 years; patients were usually never- or former-smokers (99%) with adenocarcinoma histology (97%). Most patients were heavily pretreated, with 44% receiving ≥3 prior treatments. At a median follow-up of 11 months (95% CI: 9.2, 12.8 months), ORR was 61% (95% CI: 52%, 70%), including 2 CRs and 69 PRs, and clinical benefit rate (CR+PR+SD) was 88%. Responses (CR or PR) were rapid (median 8 weeks to response). Preliminary median response duration estimate was 48 weeks (95% CI: 36 weeks, not reached). Preliminary median PFS was 10 months (95% CI: 8, 15 months). Median OS has not been reached. Treatment-related AEs were mostly Grade 1/2 with vision disorder (63%) and GI events (nausea, 54%; diarrhea, 49%; vomiting, 40%) the most common. These AEs typically had an early onset (Cycle 1) and diminished as treatment continued. Conclusions: In patients with ALK-positive NSCLC, the efficacy of crizotinib was robust, rapid, durable and clinically meaningful. The most common AEs with crizotinib were either self-limiting or easily managed. Crizotinib may offer a new standard of care for patients with ALK-positive advanced NSCLC, a subgroup that currently lacks any approved agent specific to the molecular diagnosis. Best response to crizotinib therapy. Group (N=116) n (%) CR 2 (2) PR 69 (59) SD ≥6 weeks 31 (27) Best overall ORR (CR + PR) 71 (61)